Immutep Limited (FRA:YP1B)

Market Cap	211.84M
Revenue (ttm)	2.82M
Net Income (ttm)	-34.30M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,479
Open	0.1310
Previous Close	0.1240
Day's Range	0.1310 - 0.1310
52-Week Range	0.1080 - 0.2140
Beta	n/a
RSI	43.44
Earnings Date	Oct 26, 2025

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YP1B

Financial Performance

In 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD